IDEAYA Biosciences (IDYA) Current Deferred Revenue (2018 - 2025)

IDEAYA Biosciences has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $490000.0 for Q3 2025.

• Current Deferred Revenue for Q3 2025 came in at $490000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $490000.0 (changed N/A YoY), and the FY2022 annual result was $8.6 million, down 70.5% from the prior year.
• Current Deferred Revenue came in at $490000.0 for Q3 2025 at IDEAYA Biosciences, down from $1.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $62.2 million in Q3 2021 to a low of $490000.0 in Q3 2025.
• The 4-year median for Current Deferred Revenue is $16.2 million (2021), against an average of $20.3 million.
• Across the five-year window, Current Deferred Revenue surged 61.98% in 2022 and slumped 92.14% in 2023, its largest moves.
• IDEAYA Biosciences' Current Deferred Revenue stood at $29.0 million in 2021, then plunged by 70.5% to $8.6 million in 2022, then plunged by 83.2% to $1.4 million in 2023, then slumped by 65.95% to $490000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $490000.0 (Q3 2025), $1.4 million (Q3 2023), and $2.8 million (Q2 2023), per Business Quant data.